Back

Notification report


Full notification file


General information

Notification Number
B/DE/17/PEI3056

Member State to which the notification was sent
Germany

Date of acknowledgement from the Member State Competent Authority
10/04/2017

Title of the Project
Phase I clinical trial of MVA-based recombinant vaccine (MVA-MERS-S) encoding Middle East Respiratory Syndrome coronavirus spike protein

Proposed period of release:
01/01/2017 to 30/09/2017

Name of the Institute(s) or Company(ies)
Universitätsklinikum Hamburg-Eppendorf (UKE), ;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Recombinant Modified Vaccinia Virus Ankara (MVA) delivering the S-glycoprotein of the Middle East Respiratory Syndrome (MERS) coronavirus, MVA-MERS-S (Song et al., 2013).
Genus: Orthopoxvirus
Species: Vaccinia virus


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
MVAOrthopoxvirusvaccinia virus-Modified vaccinia virus Ankara-

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
22/11/2018 00:00:00
Remarks: